London, UK – 15 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces its audited results for the year ended 31 December 2025. Financial highlights · Revenue of £46.8 million (2024: £62.7 million) · Positive adjusted EBITDA of £1.4 million (2024: £16.4 million) · Adjusted EBITDA margin of 3.0% (2024: 26.2%) · Basic adjusted earnings per share of (0.41)p (2024: 1.69p) ·…